Surgical management and outcomes of metastatic tumors to the ovaries

Purpose of Investigation: Gynecologic and non-gynecologic tumors occasionally metastasize to the ovaries. Aim of this study was to describe the clinicopathologic characteristics and survival outcomes of patients with metastatic tumors to the ovaries. Materials and Methods: Between 2007-2017, 859 operations were performed in this center with initial diagnosis of ovarian mass. Seventy-five patients who had metastatic tumor to the ovaries in pathological examination were included the study. Results: Median overall survival of all patients was 26 ± 5.9 months, three-year survival was 62%, and five-year survival was 37%. Patients who developed metachronous metastasis had better survival than patients who had synchronous metastasis (p = 0.05). Bilateral ovarian involvement was related with poor survival compared with unilateral involvement. Chemotherapy had beneficial effect on overall survival. Median survival in extensive surgery group was 30.9 months and it was better than minimal surgery group with 15.6 months, however it was not statistically significant (p = 0.973). Conclusion: The prognosis of the metastatic tumors to the ovaries is poor but achieving a complete resection and optimal debulking surgery may improve survival in some histologic subgroups.

Ovarian metastasis; Krukenberg tumors; Non-genital cancers; Chemotherapy; Cytoreductive surgery

[1] Waal de Y.R., Thomas C.M., Oei A.L., Sweep F.C., Massuger L.F.: “Secondary ovarian malignancies: frequency, origin, and characteristics”. Int. J. Gynecol. Cancer, 2009, 19, 1160.

[2] Skírnisdóttir I., Gramo H., Holmberg L.: “Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990- 2003: occurrence, origin and survival compared to ovarian cancer”. Gynecol. Oncol., 2007, 105, 166.

[3] Petru E., Pickel H., Heydarfadai M., Lahousen M., Haas J., Schaider H., et al.: “Nongenital cancers metastatic to the ovary”. Gynecol. Oncol., 1992, 44, 83.

[4] Kim W.Y., Kim T.J., Kim S.E., Lee J.W., Lee J.H., Kim B.G.: “The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 149, 97.

[5] Jeung Y.J., Ok H.J., Kim W.G., Kim S.H., Lee T.H.: “Krukenberg tumors of gastric origin versus colorectal origin”. Obstet. Gynecol. Sci., 2015, 58, 32.

[6] Kubeček O., Laco J, Špaček J., Petera J., Kopecký J, Kubečková A., et al.: “The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review”. Clin. Exp. Metastasis, 2017,34, 295.

[7] Shah B., Tang W., Karn S.: “An Up-to-Date Understanding of the “Krukenberg Tumor” Mechanism”. Adv. Reprod. Sci., 2016, 4, 31.

[8] Wu F., Zhao X., Mi B., Feng L.U., Yuan N.A., Lei F., et al.: “Clinical characteristics and prognostic analysis of Krukenberg tumor”, Mol. Clin. Oncol., 2015, 3, 1323.

[9] Ayhan A, Guvenal T, Salman M.C., Ozyuncu O., Sakinci M, Basaran M.: “The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries”. Gynecol. Oncol., 2005, 98, 235.

[10] Brigand C., Monneuse O, Mohamed F., Sayag-Beaujard A.C., Isaac S., Gilly F.N., et al: “Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study”. Ann. Surg. Oncol., 2006, 13, 405.

[11] Jeung Y.J., Ok H.J., Kim W.G., Kim S.H., Lee T.H.: “Krukenberg tumors of gastric origin versus colorectal origin”. Obstet. Gynecol. Sci., 2015, 58, 32.

[12] Fianza A.. La, Alberici E.., Pistorio A., Generoso P.: “Differential diagnosis of Krukenberg tumors using multivariate analysis”. Tumori, 2002, 88, 284.

[13] Moore R.G., Chung M, Graini C.O., Gajewski W., Steinhoff M.M.: “Incidence of metastasis to the ovaries from nongenital tract primary tumors”. Gynecol. Oncol., 2004, 93, 87.

[14] Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al.: “Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study”. J. Clin. Oncol., 2008, 26, 2013.

[15] Stintzing S., Modest D.P., Rossius L., Lerch M.M., von Weikersthal L.F., Decker T., et al.: “FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial”. Lancet Oncol., 2016, 17, 1426.

[16] Ganesh K., Shah R.H., Vakiani E., Nash G.M., Skottowe H.P., Yaeger R., et al.: “Clinical and genetic determinants of ovarian metastases from colorectal cancer”. Cancer, 2017, 123, 1134.

[17] Bigore V., Morice P., Duvillard P, Antoine M., Cortez A, Flejou J.F., et al.: “Ovarian Metastases From Breast Cancer Report of 29 Cases”. Cancer, 2010, 116, 799.